Innovacell Inc. is a biotechnology company based in Tokyo, Japan, focused on developing and manufacturing regenerative medicine products for treating fecal and urinary incontinence. The company specializes in cell therapy solutions aimed at addressing significant unmet medical needs in these areas. Its notable products include ICEF15, a cell therapy for urgent fecal incontinence; ICEF16 for leaky fecal incontinence; and ICES13 for stress urinary incontinence. Innovacell went public on the Tokyo Stock Exchange Growth Market on February 24, 2026, under the ticker symbol 504A, offering approximately 9.13 million shares at an indicative price range of 1,290 to 1,350 yen per share, aiming to raise about 12.32 billion yen. As of July 2026, the company employed 48 people. Recent developments include a 1 billion yen investment from Alfresa Corporation and successful completion of a Series D funding round, raising over 7.3 billion yen.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Innovacell Inc.'s offering is currently listed on JPX. The expected date is Feb 24, 2026. Shares are expected to be offered at $9.00, with 8.4M shares on offer. The proposed ticker is 504A. Innovacell Inc. is headquartered in Japan.
Innovacell Inc. is expected to list on Feb 24, 2026.
Innovacell Inc. is listing on JPX.
Innovacell Inc.'s proposed ticker is 504A.
Innovacell Inc. is a biotechnology company based in Tokyo, Japan, focused on developing and manufacturing regenerative medicine products for treating fecal and urinary incontinence. The company specializes in cell therapy solutions aimed at addressing significant unmet medical needs in these areas. Its notable products include ICEF15, a cell therapy for urgent fecal incontinence; ICEF16 for leaky fecal incontinence; and ICES13 for stress urinary incontinence. Innovacell went public on the Tokyo Stock Exchange Growth Market on February 24, 2026, under the ticker symbol 504A, offering approximately 9.13 million shares at an indicative price range of 1,290 to 1,350 yen per share, aiming to raise about 12.32 billion yen. As of July 2026, the company employed 48 people. Recent developments include a 1 billion yen investment from Alfresa Corporation and successful completion of a Series D funding round, raising over 7.3 billion yen.
Japan Exchange Group new-listings page. Retrieved Aug 3, 2026.
View the original filing on JPX →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy